Meliane 0.020 mg/0.075 mg Side effects

Is this medication very expensive?

Side effects of Meliane 0.020 mg/0.075 mg in details

A side effect of any drug can be defined as the unwanted or undesired effect produced by the drug. The side effect can be major or in few medications minor that can be ignored. Side effects not only vary from drug to drug, but it also depends on the dose of the drug, the individual sensitivity of the person, brand or company which manufactures it. If side effects overweigh the actual effect of the medicine, it may be difficult to convince the patient to take the drug. Few patients get specific side effects to specific drugs; in that case, a doctor replaces the drug with another. If you feel any side effect and it troubles you, do not forget to share with your healthcare practitioner.

The most serious adverse reactions associated with the use of oral contraceptives are indicated under Warnings and Precautions.

Adverse reactions are listed per CIOMS frequency categories: Very Common: ≥10%; Common: ≥1% and <10%; Uncommon: ≥0.1% and <1%; Rare: ≥0.01% and <0.1%; Very rare: <0.01%.

Use of COCs has been associated with increased risk of arterial and venous thrombotic and thromboembolic events, including myocardial infarction, stroke, transient ischemic attack, venous thrombosis and pulmonary embolism; cervical intraepithelial neoplasia and cervical cancer; breast cancer diagnosis; benign hepatic tumors (eg, focal nodular hyperplasia, hepatic adenomas).

Infections and Infestations: Common: Vaginitis, including candidiasis.

Neoplasms (Benign, Malignant and Unspecified): Very Rare: Hepatocellular carcinomas.

Immune System Disorders: Rare: Anaphylactic/anaphylactoid reactions, including very rare cases of urticaria, angioedema, and severe reactions with respiratory and circulatory symptoms. Very Rare: Exacerbation of systemic lupus erythematosus. Other reactions of possible immunologic origin may be listed under other organ system subheadings.

Metabolism and Nutrition Disorders: Uncommon: Changes in appetite (increase or decrease). Rare: Glucose intolerance. Very Rare: Exacerbation of porphyria.

Psychiatric Disorders: Common: Mood changes, including depression; changes in libido.

Nervous System Disorders: Very Common: Headache, including migraines. Common: Nervousness; dizziness. Very Rare: Exacerbation of chorea.

Eye Disorders: Rare: Intolerance to contact lenses. Very Rare: Optic neuritis (may lead to partial or complete loss of vision); retinal vascular thrombosis.

Vascular Disorders: Very Rare: Aggravation of varicose veins.

Gastrointestinal Disorders: Common: Nausea; vomiting; abdominal pain. Uncommon: Abdominal cramps; bloating. Very Rare: Pancreatitis, ischemic colitis.

Hepatobiliary Disorders: Rare: Cholestatic jaundice. Very Rare: Gallbladder disease, including gallstones (COCs may worsen existing gallbladder disease and may accelerate the development of this disease in previously asymptomatic women). Unknown: Hepatocellular injury (eg, hepatitis, abnormal hepatic function).

Skin and Subcutaneous Tissue Disorders: Common: Acne. Uncommon: Rash; chloasma (melasma), which may persist; hirsutism; alopecia. Rare: Erythema nodosum. Very Rare: Erythema multiforme.

Renal and Urinary Disorders: Very Rare: Hemolytic uremic syndrome.

Reproductive System and Breast Disorders: Very Common: Breakthrough bleeding/spotting. Common: Breast pain, tenderness, enlargement, secretion; dysmenorrhea; change in menstrual flow; change in cervical ectropion and secretion; amenorrhea.

General Disorders and Administration Site Conditions: Common: Fluid retention/edema.

Investigations: Common: Changes in weight (increase or decrease). Uncommon: Increase in blood pressure; changes in serum lipid levels, including hypertriglyceridemia. Rare: Decrease in serum folate levels (Serum folate levels may be depressed by COC therapy. This may be of clinical significance if the woman becomes pregnant shortly after discontinuing COCs).

Meliane 0.020 mg/0.075 mg contraindications

Contraindication can be described as a special circumstance or a disease or a condition wherein you are not supposed to use the drug or undergo particular treatment as it can harm the patient; at times, it can be dangerous and life threatening as well. When a procedure should not be combined with other procedure or when a medicine cannot be taken with another medicine, it is called Relative contraindication. Contraindications should be taken seriously as they are based on the relative clinical experience of health care providers or from proven research findings.

History of venous thromboembolism, markedly impaired liver function or cholestasis, Dubin-Johnson or Rotor syndromes, hepatic adenoma, estrogen-dependent neoplasms eg, breast or endometrial cancer, cardiovascular disease including previous, current or if at high risk of thromboembolic disorders and arterial disease or multiple risk factors for it, disorders of lipid metabolism, undiagnosed vaginal bleeding, possible pregnancy or a history of pruritus itchiness or cholestatic jaundice during pregnancy, chorea, herpes gestationis, pemphigoid gestationis, deteriorating otosclerosis, severe or focal migraine (or where there are other risk factors for cardiovascular disease).

Smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases depending on the age and frequency of smoking (≥15 cigarettes/day) especially in women >35 years. Women who are using combined oral contraceptives should not smoke. Women who smoke and need contraception are advised to take progestin-only pills.

Use in pregnancy: Meliane 0.020 mg/0.075 mg is not recommended for pregnant women. Pregnancy must be ruled out before taking Meliane 0.020 mg/0.075 mg. Should a pregnancy occur while taking the tablet, the administration has to be withdrawn at once.

Use in lactation: Breastfeeding mothers should not take Meliane 0.020 mg/0.075 mg. This can reduce the volume of breast milk. Breastfeeding women are advised to take progestin-only pills.



  1. European Chemicals Agency - ECHA. "Gestodene: The information provided here is aggregated from the "Notified classification and labelling" from ECHA's C&L Inventory. ". (accessed September 17, 2018).
  2. HSDB. "GESTODENE". (accessed September 17, 2018).
  3. KEGG. "Cytochrome P450 interactions". (accessed September 17, 2018).


The results of a survey conducted on for Meliane 0.020 mg/0.075 mg are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Meliane 0.020 mg/0.075 mg. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported side effects

No survey data has been collected yet

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name: 
Spam protection:  < Type 21 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2021 All Rights Reserved